title: SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments
source: Yahoo
date: 2025-10-21
url: https://finnhub.io/api/news?id=759448bc8672bea87d54cfd23678b9036f8c6968e1c4ddee0158191ed9bcc855
Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.
